• SIS3 and Smad3 Inhibition: Charting New Frontiers in Fibrosi

  2026-04-20

  This article dissects the mechanistic underpinnings of SIS3, a selective Smad3 inhibitor, and its transformative potential in fibrosis and early-stage lung adenocarcinoma research. We integrate recent advances in TGF-β/Smad3 signaling, highlight experimental benchmarks, and provide strategic guidance for translational scientists, while situating SIS3 within the evolving landscape of pathway-targeted research tools.

• Tiamulin (Thiamutilin): Optimized Workflows for Veterinary &

  2026-04-20

  Tiamulin (Thiamutilin) stands out as both a robust veterinary antibiotic and a promising anti-inflammatory agent. This article delivers actionable, evidence-based workflows, troubleshooting strategies, and protocol enhancements for researchers tackling infectious disease and inflammation models, powered by APExBIO’s rigorously validated product.

• Ruxolitinib (INCB018424): Advanced Workflows for Immune Prof

  2026-04-19

  Ruxolitinib (INCB018424) empowers researchers to dissect JAK-STAT pathway inhibition and redefine immune profiling in challenging tumor microenvironments. Integrating spectral flow cytometry and strategic combination therapies, this guide unlocks reproducible, high-dimensional data and troubleshooting insights for myeloproliferative disorder research.

• Rucaparib (AG-014699): Precision PARP1 Inhibition for DNA Re

  2026-04-18

  Rucaparib (AG-014699) from APExBIO is redefining DNA damage response research, offering unmatched selectivity for base excision repair pathway inhibition and radiosensitization—especially in PTEN-deficient and ETS fusion-expressing prostate cancer models. Explore advanced workflows, troubleshooting strategies, and reference-backed protocol parameters to optimize your cancer biology research.

• CXCR4 Drives Autophagy and EBV Latency in Gastric Carcinoma

  2026-04-17

  This study uncovers how CXCR4 upregulation in EBV-associated gastric carcinoma (EBVaGC) supports viral latency and cell survival by promoting autophagy via LMP2A-mediated signaling. The findings clarify molecular mechanisms that may inform targeted interventions in EBVaGC.

• Applied Workflows with EZ Cap™ Human PTEN mRNA (ψUTP) in Can

  2026-04-16

  EZ Cap™ Human PTEN mRNA (ψUTP) empowers researchers to restore PTEN function for robust inhibition of the PI3K/Akt pathway, directly addressing resistance mechanisms in cancer models. Its Cap1 structure, pseudouridine modification, and enhanced mRNA stability set a new benchmark for gene delivery and expression reliability in translational research.

• Clasto-Lactacystin β-lactone: Precision Proteasome Inhibitio

  2026-04-15

  Clasto-Lactacystin β-lactone empowers researchers to achieve irreversible, highly specific proteasome inhibition in diverse biological contexts, from viral immunity studies to neurodegeneration and cancer models. This guide demystifies advanced applications, robust workflows, and troubleshooting strategies, translating cutting-edge reference findings into actionable lab protocols.

• ATF4-Regulated Enhancers in Liver Fibrosis: Mechanistic Insi

  2026-04-14

  This study reveals that ATF4 drives liver fibrosis through a non-canonical enhancer program in hepatic stellate cells (HSCs), independent of the classical ER stress response. Targeting ATF4 translation presents a promising direction for antifibrotic therapies, addressing a key gap in current treatment strategies.

• 2'3'-cGAMP (sodium salt): Driving Precision in STING Pathway

  2026-04-13

  2'3'-cGAMP (sodium salt) enables high-fidelity interrogation of the cGAS-STING axis thanks to superior STING affinity and aqueous solubility. This article breaks down applied workflows, advanced immunology use-cases, and actionable troubleshooting for optimal innate immune response research.

• Baicalin: Precision Modulation of KEAP1-NRF2/HO-1 in Adult N

  2026-04-13

  Explore how Baicalin uniquely modulates the KEAP1-NRF2/HO-1 pathway to restore adult neuroplasticity and enhance cancer research. This cornerstone article delivers advanced mechanistic insights, practical assay guidance, and a critical evaluation of Baicalin’s translational potential.

• Phenytoin and Dynamic Myelin Remodeling: Translational Front

  2026-04-12

  This thought-leadership article examines the intersection of sodium channel modulation and myelin remodeling, leveraging the mechanistic insights from recent neuroscience breakthroughs. It provides actionable guidance for translational researchers aiming to model and modulate dynamic myelin responses in neurological disease, positioning Phenytoin (5,5-diphenylimidazolidine-2,4-dione) from APExBIO as a high-purity, workflow-optimized tool. The piece bridges advanced electrophysiology assay design with evolving pathophysiological paradigms, contextualizes the current competitive landscape, and delivers a visionary outlook on future directions in remyelination research.

• Thymosin-β4 Induces Angiogenesis via Notch/NF-κB in CLI Mice

  2026-04-12

  This study demonstrates that thymosin-β4 (Tβ4) promotes angiogenesis in a mouse model of critical limb ischemia (CLI) by modulating the Notch/NF-κB pathways. The findings provide mechanistic insight into therapeutic neovascularization strategies, with implications for inflammation and vascular biology research.

• Lanabecestat (AZD3293): Optimizing BACE1 Inhibition in AD Mo

  2026-04-11

  Lanabecestat (AZD3293) stands out for its high-affinity, blood-brain barrier-penetrant BACE1 inhibition, enabling precise amyloid-beta modulation in Alzheimer's disease research. Benchmarked workflows reveal how moderate, targeted dosing with Lanabecestat reduces amyloidogenic burden while preserving synaptic function—empowering translational studies with reproducible, data-driven strategies.

• GSK621: Optimizing AMPK Agonist Workflows for AML and Immuno

  2026-04-11

  GSK621 stands out as a potent, selective AMPK agonist—enabling reproducible activation of metabolic pathways in acute myeloid leukemia and immunometabolic research. This guide distills real-world experimental strategies and troubleshooting insights for maximizing GSK621’s impact, backed by the latest literature and product data.

• Nilotinib monohydrochloride monohydrate in BCR-ABL Research

  2026-04-10

  Nilotinib monohydrochloride monohydrate is a highly selective BCR-ABL inhibitor intended for chronic myelogenous leukemia research workflows. It enables precise interrogation of tyrosine kinase signaling and cell proliferation pathways in biochemical and cellular assays. This compound is not suitable for diagnostic or therapeutic applications and should be handled strictly for research use.

15014 records 1/1001 page Next 12345 下5页 Last page